Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2024, Quick Ratio deteriorated to 0.22 below Vaccinex Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 430 other companies have achieved higher Quick Ratio than Vaccinex Inc in fourth quarter 2024. While Quick Ratio total ranking in the fourth quarter 2024 has deteriorated compared to the prior quarter from 2208 to 3165.

Explain Quick Ratio?
How much Cash & cash equivalents VCNX�s has?
What are VCNX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

VCNX Quick Ratio	(Dec 31 2024) Q4	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1	(Dec 31 2023) Q4
Y / Y Current Liabilities Change	-14.06 %	-0.32 %	62.66 %	119.6 %	149.3 %
Y / Y Cash & cash equivalent Change	-27.88 %	2188.19 %	-87.79 %	-10.56 %	-75.98 %
Quick Ratio MRQ	0.22	0.47	0.04	0.63	0.26
VCNX's Total Ranking	# 3165	# 2208	# 3740	# 2226	# 3149
Seq. Current Liabilities Change	-17.67 %	18.05 %	11.16 %	-20.45 %	-4.5 %
Seq. Cash & cash equivalent Change	-61.91 %	1147.21 %	-92.16 %	93.62 %	1108.66 %

Quick Ratio fourth quarter 2024 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 431
Healthcare Sector	# 835
Overall Market	# 3165

Quick Ratio Statistics
High	Average	Low
10.01	2.22	0.02
(Mar 31 2022)		(Sep 30 2023)

Financial Statements
Vaccinex Inc 's Current Liabilities	$ 5 Millions	Visit VCNX's Balance sheet
Vaccinex Inc 's Cash & cash equivalent	$ 1 Millions	Visit VCNX's Balance sheet
Source of VCNX's Sales		Visit VCNX's Sales by Geography

Cumulative Vaccinex Inc 's Quick Ratio

VCNX's Quick Ratio for the trailling 12 Months

VCNX Quick Ratio	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months
Y / Y Current Liabilities TTM Growth	21.33 %	58.17 %	130.72 %	157.69 %	139.02 %
Y / Y Cash & cash equivalent TTM Growth	4.71 %	-34.92 %	-74.12 %	-76.88 %	-83.5 %
Quick Ratio TTM	0.34	0.35	0.22	0.33	0.39
Total Ranking TTM	# 3727	# 1805	# 3453	# 3719	# 4021
Seq. Current Liabilities TTM Growth	-3.78 %	-0.09 %	10.06 %	14.67 %	25.44 %
Seq. Cash & cash equivalent TTM Growth	-5.6 %	57.1 %	-25.6 %	-5.09 %	-41.33 %

Quick ratio ranking by company, industry and sector >> Back to VCNX Financial Strength Comparisons >> Go to Compare VCNX Quick Ratio to its Competitors

News about Vaccinex Inc Quick Ratio

Vaccinex Announces Pricing of $3.7 Million PIPE Financing to Accelerate Research in Neurodegenerative Disease Treatmentnn

ROCHESTER, N.Y., Feb. 07, 2024 Vaccinex, Inc. (Nasdaq: VCNX) (Vaccinex or the Company) has made a significant announcement today regarding a private placement transaction. The clinical-stage biotechnology company, known for its innovative approach to treating neurodegenerative diseases, has successfully priced a $3.7 million financing round with a lead investment from a major new investor. Existing investors, including entities associated with the Chairman of the Board of Directors and the Chief Executive Officer, have also participated significantly in this round.
The financing involves the sale of 3,838,544 shares of the Company s common stock, as well as common warrants to purchase up to 5,103,622 additional shares. The combined purchase price per share and warrant is set at $0.725, with the common warrants having an exercise price of $1.00 per share. Notably, the warrants will be immediately exercisable and will expire five years from the initial exercise date, unless the Company decides to call them within 120 days after reporting specific positive data from the ongoing SIGNAL-AD phase 1/2a clinical trial of their lead drug candidate, pepinemab, in Alzheimers disease.

On the trailing twelve months basis In spite of the year on year decrease in VCNX's Current Liabilities to $5.08 millions, cumulative Quick Ratio to 0.34 below the VCNX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 460 other companies have achieved higher Quick Ratio than Vaccinex Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2024 from 1805 to 3727.

Explain Quick Ratio?
How much Cash & cash equivalents VCNX�s has?
What are VCNX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 461
Healthcare Sector	# 949
Within the Market	# 3727

trailing twelve months Quick Ratio Statistics
High	Average	Low
6.57	2.08	0.27
(Jun 30 2022)		(Jun 30 2024)

Companies with similar Quick Ratio in the quarter ending Dec 31 2024, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2024 MRQ Cash & cash equivalent	Dec 31 2024 MRQ Current Liabilities
Esperion Therapeutics Inc	0.59	$ 144.761 Millions	$ 246.233 Millions
Journey Medical Corp	0.58	$ 20.305 Millions	$ 35.175 Millions
Cumberland Pharmaceuticals Inc	0.57	$ 17.964 Millions	$ 31.265 Millions
Elite Pharmaceuticals Inc	0.55	$ 7.201 Millions	$ 13.050 Millions
Edesa Biotech Inc	0.55	$ 1.000 Millions	$ 1.813 Millions
Nls Pharmaceutics Ltd	0.54	$ 1.300 Millions	$ 2.393 Millions
Quantum Biopharma Ltd	0.54	$ 5.996 Millions	$ 11.041 Millions
Supernus Pharmaceuticals inc	0.54	$ 69.331 Millions	$ 129.532 Millions
Aurinia Pharmaceuticals Inc	0.53	$ 83.396 Millions	$ 158.050 Millions
Optinose Inc	0.52	$ 84.485 Millions	$ 162.813 Millions
23andme Holding Co	0.52	$ 79.350 Millions	$ 153.340 Millions
Harrow Inc	0.52	$ 47.247 Millions	$ 91.343 Millions
Tiziana Life Sciences Ltd	0.52	$ 3.724 Millions	$ 7.230 Millions
Oragenics Inc	0.51	$ 0.865 Millions	$ 1.684 Millions
Summit Therapeutics Inc	0.51	$ 16.363 Millions	$ 31.874 Millions
Igc Pharma Inc	0.51	$ 1.198 Millions	$ 2.343 Millions
Xencor Inc	0.50	$ 43.192 Millions	$ 86.123 Millions
Bio Green Med Solution Inc	0.50	$ 3.137 Millions	$ 6.268 Millions
Earth Science Tech Inc	0.50	$ 0.707 Millions	$ 1.416 Millions
Biofrontera Inc	0.49	$ 5.905 Millions	$ 12.021 Millions
Merck and Co Inc	0.48	$ 13,689.000 Millions	$ 28,420.000 Millions
Immunoprecise Antibodies Ltd	0.48	$ 2.967 Millions	$ 6.223 Millions
Elanco Animal Health Incorporated	0.48	$ 468.000 Millions	$ 983.000 Millions
Bristol myers Squibb Company	0.46	$ 10,859.000 Millions	$ 23,774.000 Millions
Citius Pharmaceuticals Inc	0.45	$ 3.252 Millions	$ 7.156 Millions
Grifols Sa	0.45	$ 1,097.354 Millions	$ 2,414.884 Millions
Biodexa Pharmaceuticals Plc	0.45	$ 2.242 Millions	$ 5.034 Millions
Galectin Therapeutics Inc	0.43	$ 15.120 Millions	$ 35.409 Millions
Jaguar Health Inc	0.41	$ 8.002 Millions	$ 19.704 Millions
Prestige Consumer Healthcare Inc	0.40	$ 46.469 Millions	$ 117.048 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.